Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Hydrolyzed Rutin Decreases Worsening of Anaplasia in Glioblastoma Relapse

Author(s): Carlos Tadeu Parisi de Oliveira, Renato Colenci, Cesar Cozar Pacheco, Patrick Moro Mariano, Paula Ribeiro do Prado, Gustavo Pignatari Rosas Mamprin, Maycon Giovani Santana, Alessandra Gambero, Patrícia de Oliveira Carvalho and Denise Gonçalves Priolli*

Volume 18, Issue 5, 2019

Page: [405 - 412] Pages: 8

DOI: 10.2174/1871527318666190314103104

Price: $65

Abstract

Background: Gliomas are aggressive and resilient tumors. Progression to advanced stages of malignancy, characterized by cell anaplasia, necrosis, and reduced response to conventional surgery or therapeutic adjuvant, are critical challenges in glioma therapy. Relapse of the disease poses a considerable challenge for management. Hence, new compounds are required to improve therapeutic response. As hydrolyzed rutin (HR), a compound modified via rutin deglycosylation, as well as some flavonoids demonstrated antiproliferative effect for glioblastoma, these are considered potential epigenetic drugs.

Objective: The purpose of this study was to determine the antitumor activity and evaluate the potential for modifying tumor aggressivity of rutin hydrolysates for treating both primary and relapsed glioblastoma.

Methods: The glioblastoma cell line, U251, was used for analyzing cell cycle inhibition and apoptosis and for establishing the GBM mouse model. Mice with GBM were treated with HR to verify antitumor activity. Histological analysis was used to evaluate HR interference in aggressive behavior and glioma grade. Immunohistochemistry, comet assay, and thiobarbituric acid reactive substance (TBARS) values were used to evaluate the mechanism of HR action.

Results: HR is an antiproliferative and antitumoral compound that inhibits the cell cycle via a p53- independent pathway. HR reduces tumor growth and aggression, mainly by decreasing mitosis and necrosis rates without genotoxicity, which is suggestive of epigenetic modulation.

Conclusion: HR possesses antitumor activity and decreases anaplasia in glioblastoma, inhibiting progression to malignant stages of the disease. HR can improve the effectiveness of response to conventional therapy, which has a crucial role in recurrent glioma.

Keywords: Glioblastoma, cancer, flavonoid, animal model, anaplasia, relapses.

« Previous Next »
Graphical Abstract

[1]
Sanchez-Perez Y, Soto-Reyes E, Garcia-Cuellar CM, Cacho-Diaz B, Santamaria A, Rangel-Lopez E. Role of epigenetics and oxidative stress in gliomagenesis. CNS Neurol Disord Drug Targets 2017; 16(10): 1090-8.
[2]
Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a “state of the science” review. Neur O ncol 2014; 16(7): 896-913.
[3]
Piñeros M, Sierra MS, Izarzugaza MI, Forman D. Descriptive epidemiology of brain and central nervous system cancers in Central and South America. Cancer Epidemiol 2016; 44(1): S141-9.
[4]
WHO. Cancer. 2018 Sep 28 [cited 2018 Dec 11]; Available from: http: //www.who.int/cancer/en/
[5]
Zhan T, Chen Y, Hong X, Lu Z, Chen Y. Brain tumor segmentation using deep belief networks and pathological knowledge. CNS Neurol Disord Drug Targets 2017; 16(2): 129-36.
[6]
Yang Z, Feng P, Wen T, Wan M, Hong X. Differentiation of glioblastoma and lymphoma using feature extraction and support vector machine. CNS Neurol Disord Drug Targets 2017; 16(2): 160-8.
[7]
Baumann F, Bjeljac M, Kollias SS, et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol 2004; 67(1-2): 191-200.
[8]
Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs 2016; 20(5): S2-8.
[9]
Roy S, Lahiri D, Maji T, Biswas J. Retraction: recurrent glioblastoma: where we stand. South Asian J Cancer 2017; 6(4): 153.
[10]
Ramírez-Expósito MJ, Martínez-Martos JM. Differential effects of doxazosin on renin-angiotensin-system-regulating aminopeptidase activities in neuroblastoma and glioma tumoral cells. CNS Neurol Disord Drug Target 2018. Available from:
[http://dx.doi.org/10.2174/1871527317666181029111739]
[11]
Zhang Z, Li C, Tan Q, et al. Curcumin suppresses tumor growth and angiogenesis in human glioma cells through modulation of vascular endothelial growth factor/angiopoietin-2/thrombospondin-1 signaling. CNS Neurol Disord Drug Target 2017; 16(3): 346-50.
[12]
Gokul S, Rajanikant GK. Research highlights BAY 1436032: a novel pan-mutant IDH1 inhibitor extends survival of mice with experimental brain tumors. CNS Neurol Disord Drug Target 2017; 16(6): 636-7.
[13]
de Araújo MEMB, Moreira Franco YE, Alberto TG, et al. Enzymatic de-glycosylation of rutin improves its antioxidant and antiproliferative activities. Food Chem 2013; 141(1): 266-73.
[14]
Website [Internet]. [cited 2018 Dec 11]. Available from: http: //oecd.org/ehs/test/testlist.htm
[15]
Tomayko MM, Patrick RC. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24(3): 148-54.
[16]
Martins F, Suzan AJ, Cerutti SM, et al. Consumption of mate tea (Ilex paraguariensis) decreases the oxidation of unsaturated fatty acids in mouse liver. Br J Nutr 2008; 101(04): 519.
[17]
Ribeiro ML, Priolli DG, Miranda DDC, Arçari DP, Pedrazzoli J, Martinez CAR. Analysis of oxidative DNA damage in patients with colorectal cancer. Clin Colorectal Cancer 2008; 7(4): 267-72.
[18]
Priolli DG, Canelloi TP, Lopes CO, et al. Oxidative DNA damage and β-catenin expression in colorectal cancer evolution. Int J Colorectal Dis 2013; 28(5): 713-22.
[19]
Scalise JR, Poças RCG, Caneloi TP, et al. DNA damage is a potential marker for tp53 mutation in colorectal carcinogenesis. J Gastrointest Cancer 2016; 47(4): 409-16.
[20]
Website [Internet]. [cited 2018 Dec 11]. Available from: http: www.publicacoesdeturismo.com.br\calculoamostral
[21]
Cengiz P, Zemlan F, Eickhoff JC, Ellenbogen R, Zimmerman JJ. Increased cerebrospinal fluid cleaved tau protein (C-tau) levels suggest axonal damage in pediatric patients with brain tumors. Childs Nerv Syst 2015; 31(8): 1313-9.
[22]
Pan HC, Jiang Q, Yu Y, Mei JP, Cui YK, Zhao WJ. Quercetin promotes cell apoptosis and inhibits the expression of MMP-9 and fibronectin via the AKT and ERK signalling pathways in human glioma cells. Neurochem Int 2015; 80: 60-71.
[23]
Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4(12): 988-1004.
[24]
Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 2004; 22(10): 1926-33.
[25]
Vauzour D, Vafeiadou K, Rice-Evans C, Williams RJ, Spencer JPE. Activation of pro-survival Akt and ERK1/2 signalling pathways underlie the anti-apoptotic effects of flavanones in cortical neurons. J Neurochem 2007; 103(4): 1355-67.
[26]
Kim B-H, Choi JS, Yi EH, et al. Relative antioxidant activities of quercetin and its structurally related substances and their effects on NF-κB/CRE/AP-1 signaling in murine macrophages. Mol Cells 2013; 35(5): 410-20.
[27]
Wang L, Gao S, Jiang W, et al. Antioxidative dietary compounds modulate gene expression associated with apoptosis, DNA repair, inhibition of cell proliferation and migration. Int J Mol Sci 2014; 15(9): 16226-45.
[28]
Amado NG, Fonseca BF, Cerqueira DM, Neto VM, Abreu JG. Flavonoids: potential Wnt/beta-catenin signaling modulators in cancer. Life Sci 2011; 89(15-16): 545-54.
[29]
Zhang Y, Dube C, Gibert M Jr, Cruickshanks N, et al. The p53 pathway in glioblastoma. Cancers (Basel) 2018; 10(9) Pii: E297
[30]
Panieri E, Santoro MM. ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis 2016; 7(6)e2253
[31]
Zhang P, Sun S, Li N, et al. Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition. J Neurooncol 2017; 132(3): 393-400.
[32]
Gentile MT, Ciniglia C, Reccia MG, et al. Ruta graveolens L. induces death of glioblastoma cells and neural progenitors, but not of neurons, via ERK 1/2 and AKT activation. PLoS One 2015; 10(3)e0118864
[33]
Bie L, Zhao G, Cheng P, et al. The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression. PLoS One 2011; 6(10)e25631
[34]
Liu S, Wang Y, Xu K, et al. Relationship between necrotic patterns in glioblastoma and patient survival: fractal dimension and lacunarity analyses using magnetic resonance imaging. Sci Rep 7(1): 8302.
[35]
Aherne SA, O’Brien NM. Mechanism of protection by the flavonoids, quercetin and rutin, against tert-butylhydroperoxide- and menadione-induced DNA single strand breaks in Caco-2 cells. Free Radic Biol Med 2000; 29(6): 507-14.
[36]
Braganhol E, Zamin LL, Canedo AD, et al. Antiproliferative effect of quercetin in the human U138MG glioma cell line. Anticancer Drugs 2006; 17(6): 663-71.
[37]
Cao G, Sofic E, Prior RL. Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. Free Radic Biol Med 1997; 22(5): 749-60.
[38]
Magalingam KB, Radhakrishnan A, Haleagrahara N. Rutin, a bioflavonoid antioxidant protects rat pheochromocytoma (PC-12) cells against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity. Int J Mol Med 2013; 32(1): 235-40.
[39]
Bombardi Duarte AC, Santana MG, di Camilo Orfali G, de Oliveira CTP, Priolli DG. Literature evidence and ARRIVE assessment on neuroprotective effects of flavonols in neurodegenerative diseases’ models. CNS Neurol Disord Drug Targets 2018; 17(1): 34-42.
[40]
HEDD [cited 2018 Dec 11]. Available from: http: //hedds.org/ druglist.jsp
[41]
Majid S, Kikuno N, Nelles J, et al. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res 2008; 68(8): 2736-44.
[42]
Le UM, Hartman A, Pillai G. Enhanced selective cellular uptake and cytotoxicity of epidermal growth factor-conjugated liposomes containing curcumin on EGFR-overexpressed pancreatic cancer cells. J Drug Target 2018; 26(8): 676-83.
[43]
Zappe K, Pointner A, Switzeny OJ, et al. Counteraction of oxidative stress by vitamin e affects epigenetic regulation by increasing global methylation and gene expression of and dose dependently in Caco-2 cells. Oxid Med Cell Longev 2018; 20183734250
[44]
Jagtap S, Meganathan K, Wagh V, Winkler J, Hescheler J, Sachinidis A. Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr Med Chem 2009; 16(12): 1451-62.
[45]
Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008; 14: 312-2.
[46]
Wang RH, Zheng Y, Kim HS, et al. Interplay among BRCA1, SIRT1, and survivin during BRCA1-associated tumorigenesis. Mol Cell 2008; 32: 11-20.
[47]
Qu Y1. Zhang J, Wu S, Li B, Liu S, Cheng J. SIRT1 promotes proliferation and inhibits apoptosis of human malignant glioma cell lines. Neurosci Lett 2012; 525(2): 168-72.
[48]
Tie FL, Charles E. Deacetylation by SIRT1 reprograms inflammation and cancer. Genes Cancer 2013; 4(3-4): 135-47.
[49]
Martins IJ. Single gene inactivation with implications to diabetes and multiple organ dysfunction syndrome. J Clin Epigenet 2017; 3(3): 24.
[50]
Qiao L, Xiu YC, Ji Z, Yong LY, Wen Z, Bo W. Upregulation of SIRT1 contributes to the cardioprotective effect of Rutin against myocardial ischemia reperfusion injury in rats. J Funct Foods 2018; 46: 227-36.

Rights & Permissions Print Cite
Article Metrics
62
4
2
1
© 2024 Bentham Science Publishers | Privacy Policy